E Fund Management (HK)’s Takeda Pharmaceutical TAK Stock Holding History

E Fund Management (HK)’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.3K	Buy	1,081 +275	+34%	+$4.55K	0.01%	346
2026 Q1	$14.9K	Buy	+806	New	+$14.1K	0.01%	253

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

E Fund Management (HK)'s TAK Position: Q2 2026 in Review

E Fund Management (HK) increased its Takeda Pharmaceutical (TAK) stake by 34% in Q2 2026, buying an estimated $4.55K and bringing the position to 1,081 shares worth $17.3K. The position accounts for 0.01% of the portfolio, ranked #346.

E Fund Management (HK) first reported a position in TAK in Q1 2026 and has held it in 2 quarters since. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

E Fund Management (HK) held 1,081 shares of Takeda Pharmaceutical worth $17.3K as of Q2 2026.
E Fund Management (HK) bought 275 Takeda Pharmaceutical shares in Q2 2026, an estimated $4.55K.
Takeda Pharmaceutical made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #346 holding.
E Fund Management (HK) first reported a position in Takeda Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.